Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Last trade$57.88
Day change+$0.40 (+0.70%)
Day range$56.87 – $58.90
Volume307,022
Market cap$2.93B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.93B
Price / earnings
88.06×
Price / book
7.64×
Price / sales
9.05×
EV / sales
8.64×
EV / EBITDA
69×
Profitability
Earnings per share
$0.65
Return on assets
6.44%
Return on equity
8.67%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.13×
Quick ratio
4.82×
Cash ratio
2.44×
Cash flow
Price / cash flow
44.91×
Price / free cash flow
50.67×
Free cash flow
$57.89M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VCEL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$85.37M
$77.46M
$68.43M
$92.92M
$67.5M
$63.24M
$52.6M
$75.38M
Cost of revenue
$22.76M
$21.06M
$19.16M
$19.79M
$17.92M
$16.63M
$16.33M
$16.88M
Gross profit
$62.61M
$56.4M
$49.27M
$73.13M
$49.59M
$46.61M
$36.27M
$58.5M
Selling, general and administrative
$43.54M
$48.48M
$49.23M
$43.46M
$39.82M
$41.91M
$41.8M
$35.1M
Research and development
$6.89M
$7.49M
$8.1M
$7.25M
$6.32M
$6.73M
$7.26M
$4.92M
Total operating expenses
$50.42M
$55.97M
$57.33M
$50.71M
$46.14M
$48.64M
$49.07M
$40.02M
Operating income
$12.19M
$434K
-$8.06M
$22.42M
$3.45M
-$2.03M
-$12.79M
$18.48M
Interest expense
-$160K
-$160K
-$160K
-$162K
-$158K
-$157K
-$153K
-$154K
Income before taxes
$14.16M
$2.21M
-$6.3M
$24.1M
$5.07M
-$553K
-$11.25M
$19.96M
Income taxes
$0
$0
$0
$859K
$0
$0
$0
$148K
Net income
$14.16M
$2.21M
-$6.3M
$23.24M
$5.07M
-$553K
-$11.25M
$19.81M
Net income attributable to common shareholders
$14.16M
$2.21M
-$6.3M
$23.24M
$5.07M
-$553K
-$11.25M
$19.81M
EBITDA
$15.81M
$4.05M
-$4.8M
$25.5M
$6.39M
$797K
-$10.11M
$19.96M
Basic earnings per share
$0.28
$0.04
-$0.12
$0.46
$0.10
-$0.01
-$0.23
$0.40
Diluted earnings per share
$0.27
$0.04
-$0.12
$0.41
$0.10
-$0.01
-$0.23
$0.33
Recent news
Company coverage with links to the original publishers.
Mirum Pharmaceuticals announced positive results from the Phase III AZURE-4 study for brelovitug, an investigational treatment for chronic hepatitis delta virus (HDV). The drug met its primary endpoint with 59% and 44% response rates across two dosing regimens versus 0% for delayed treatment. Combined with positive AZURE-1 data, these two studies will support a U.S. BLA filing in the first half of 2027, with potential commercial launch expected in Q4 2027.
Vericel Corporation (VCEL) has received a Zacks Rank #1 (Strong Buy) rating due to significant upward revisions in earnings estimates. The company's consensus estimates for the current quarter and full year have increased substantially, with current-quarter earnings expected at $0.62 per share (+37.8% YoY) and full-year earnings at $0.73 per share (+128.1% YoY). The stock has gained 43.8% over the past four weeks, reflecting investor confidence in its earnings growth prospects.
Vericel Corporation reported strong Q2 2026 results with total revenue increasing 22% to $77.5 million and MACI revenue growing 23%. The company raised its full-year 2026 revenue guidance to $330-$340 million and announced a $200 million share repurchase program. Net income reached $2.2 million with free cash flow of $14.3 million, demonstrating sustained profitability and cash generation.
The global stem cell therapy market is projected to grow from USD 21.9 billion in 2025 to USD 58.5 billion by 2034, driven by technological advancements, favorable regulations, and rising demand for regenerative medicine treatments for chronic diseases. North America leads the market with 48.87% share, while Asia-Pacific emerges as a key growth engine with recent approvals of iPSC-based therapies in Japan.
Vericel Corporation announced preliminary 2025 financial results with total revenue of $276 million, driven by MACI revenue of $239.5 million. The company achieved 23% fourth quarter revenue growth, 74% gross margin, and 26% adjusted EBITDA margin, with GAAP net income profitability for the second consecutive year. The company completed its MACI sales force expansion and initiated a clinical study for MACI Ankle, while maintaining $200 million in cash with no debt.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.